Intersect ENT (XENT) Tops Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Intersect ENT Reports Third Quarter 2020 Financial Results
November 2, 2020 7:00 AM ESTMENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today reported financial results for the third quarter ended September 30, 2020.
Third Quarter 2020 Overview
Revenue of $22.7 million in the third quarter of 2020, compared to $24.1 million in the third quarter of 2019Strong sales trend reinforces confidence in fourth quarter 2020 sequential revenue growth
Cash, Cash Equivalents and Short-term Investments of $130.7 million
Total revenue was $22.7 million for the third quarter of 2020, compared to... More
